ClinicalTrials.gg
Active, not recruitingNCT05035030ASSERT-EXTUpdated Oct 23, 2026

Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

A Phase 3 interventional study of Odevixibat in Alagille Syndrome, sponsored by Albireo, an Ipsen Company. Active, not recruiting at 35 sites in 10 countries. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Albireo, an Ipsen Company (part of Ipsen) · Phase 3, Interventional, and Treatment

Updated Oct 23, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 17 studies in Alagille Syndrome with a site in United States — 5 open to participants now, 6 under way, 1 of them phase 3. Alagille Syndrome · United States.

Started
2021
with 2 others
Phase 3
2 of 17
none open now
Registered
13th of 17
by date
Lead sponsor
1 of 17
Albireo, an Ipsen Company

Among the 17 studies in Alagille Syndrome with a site in United States, this one is one of 3 that started in 2021, is one of 2 in phase 3, and was the 13th registered.

Alagille Syndrome

31 studies on the registry are indexed under Alagille Syndrome; 11 are open to participants now.

Browse Alagille Syndrome studies →

Open to participants now

5 of the 17 studies in Alagille Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Alagille Syndrome studies recruiting now, 7 (70%) set no upper age limit and 3 (30%) stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alagille Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS).

The participants of this study will have ALGS a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. Common symptoms, which often develop during the first three months of life, include blockage of the flow of bile from the liver (cholestasis), yellowing of the skin and mucous membranes (jaundice), poor weight gain and growth and severe itching (pruritis).

The drug used for the study is odevixibat and was authorized for the treatment of cholestatic pruritus in infants with ALGS over 12 months of age by the United States Food and Drug Administration on 13 June 2023.

Read the detailed description

This Phase 3, open-label, multi-center extension study will have two groups of participants: Cohort 1 (participants who participated in Study A4250-012 [NCT04674761; ASSERT] and meet the entry criteria for this study) and Cohort 2 (infants under 12 months of age) with ALGS.

The study will consist of 2 or 3 periods:

  1. A 'Treatment period' of 72 weeks (cohort 1) or 12 weeks (cohort 2). Participants will visit the clinic every 4 to 12 weeks and will receive a dose of 120 μg/kg odevixibat daily.
  2. An 'Optional extension period' where participants who wish to continue receiving odevixibat after the 'treatment period' will have the opportunity to remain on treatment with visits every 16 weeks until the drug is commercially available. The optional extension is available provided continued use is supported by the risk-benefit profile, the participant has not been previously withdrawn or discontinued from the study, and the study is not terminated by the Sponsor.
  3. A 'Safety follow-up period' of 4 weeks (cohort 1) or 2 weeks (cohort 2). The Safety Follow-up Period will not occur for those who remain on treatment in the optional extension period.

Participants will need to complete an e-diary and questionnaires throughout the study (cohort 1 only). Participants will undergo blood samplings, urine collections (cohort 1 only), physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded.

03

Conditions studied

  • Alagille Syndrome

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohort 1 :

  1. Completion of the 24-week Treatment Period of Study A4250-012
  2. Signed and assent as appropriate. Patients who turn 18 years of age (or legal age per country) during the study will be required to re-consent to remain on the study
  3. Caregivers (and age-appropriate patients) must be willing and able to use an electronic diary (eDiary) device as required by the study
  4. Sexually active males and females must agree to use a reliable method with ≤1% failure rate (such as hormonal contraception, intra-uterine device, or complete abstinence) from signed informed consent through 90 days after last dose of study drug.

Cohort 2 :

  1. Infant with clinically confirmed ALGS , ≤11 months of age at Study Day 1
  2. Body weight ≥2 kg at Study Day 1
  3. Gestational age ≥36 weeks. For children born with gestational age between 32 and 36 weeks, a postmenstrual age of ≥36 weeks is required .
  4. Signed parent/legal guardian informed consent.

Exclusion criteria

Exclusion Criteria:

Cohort 1 :

  1. Decompensated liver disease, history or presence of ascites, variceal hemorrhage, and/or encephalopathy
  2. Patients who were not compliant with study drug treatment or procedures in Study A4250-012
  3. Any other conditions or abnormalities which, in the opinion of the investigator, may compromise the safety of the patient, or interfere with the patient participating in or completing the study
  4. Known to any components of odevixibat

Cohort 2 :

  1. Patient with past medical history or ongoing presence of other types of liver disease including, but not limited to, the following:

    1. Biliary atresia of any kind
    2. Progressive familial intrahepatic cholestasis (PFIC)
    3. Benign recurrent intrahepatic cholestasis
  2. Patient with a past medical history or ongoing presence of any other disease or condition known to interfere with the absorption, distribution, metabolism (specifically bile acid metabolism), or excretion of drugs in the intestine, including but not limited to, inflammatory bowel disease
  3. Patient with past medical history or ongoing chronic diarrhea requiring intravenous fluid or nutritional intervention for treatment of the diarrhea and/or its sequelae
  4. Patient has a confirmed past diagnosis of infection with or other present and active, clinically significant chronic infection
  5. Recent infection requiring hospitalization or treatment with parenteral anti-infective within 4 weeks of Study Day 1 or completion of oral anti-infective treatment within 2 weeks prior to the Screening Visit
  6. Cancer diagnosis (except for basal cell carcinoma)
  7. Chronic kidney disease with an impaired renal function and a \<70 mL/min/1.73 m2
  8. Patient with surgical history of disruption of the enterohepatic circulation (biliary diversion surgery) within 6 months prior to the Screening Visit
  9. Patient has had a liver transplant, or a liver transplant is planned within 6 months of Study Day 1
  10. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy
  11. (INR) >1.4 (the patient may be treated with Vitamin K, and if INR is ≤1.4 at resampling the patient may be enrolled)
  12. Serum (ALT) >10 × (ULN) at Screening
  13. Serum ALT >15 × ULN at any time point during the last 6 months unless an alternate etiology was confirmed for the elevation
  14. Total >15 × ULN at Screening
  15. Patient suffers from uncontrolled, recalcitrant pruritic condition other than ALGS. Examples include, but not limited to, atopic dermatitis or other primary pruritic skin diseases.
  16. Patient exposed to alcohol or substance abuse in utero
  17. Bile acid or lipid binding resins and medications that slow gastrointestinal motility
  18. Patient has had exposure to a drug, biologic agent, or medical device within 30 days prior to the Screening Visit, or 5 half-lives of the study agent, whichever is longer
  19. Any other conditions or abnormalities which, in the opinion of the investigator may compromise the safety of the patient, or interfere with the patient participating in or completing the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Odevixibat (A4250)

    Capsules for oral administration once daily for 72 weeks.

    Drug: Odevixibat

Interventions

  • Odevixibat is a small molecule and selective inhibitor of IBAT.

    Also known as: A4250

06

What researchers measure

Primary outcomes

  1. Change from baseline in pruritus

    Assessed as change in scratching score as measured by measured by the Albireo Observer-Reported Outcome Caregiver Instrument.

    Time frame: Baseline to week 72 (cohort 1).

  2. Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is an AE that results in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: Baseline to week 12 (cohort 2).

  3. Percentage of participants with clinically significant changes from baseline in Physical Examination

    The clinical significance will be graded by the investigator.

    Time frame: Baseline to week 12 (cohort 2).

  4. Percentage of participants with clinically significant changes in Laboratory Parameters

    The following laboratory parameters will be reported: blood chemistry, hematology and coagulation. The clinical significance will be graded by the investigator.

    Time frame: Baseline to week 12 (cohort 2).

  5. Percentage of participants with clinically significant changes from baseline in Vital Signs.

    The clinical significance will be graded by the investigator.

    Time frame: Baseline to week 12 (cohort 2).

  6. Change from baseline in concomitant medications.

    Time frame: Baseline to week 12 (cohort 2).

  7. Change from baseline in fat-soluble vitamin levels.

    Time frame: Baseline to week 12 (cohort 2).

Secondary outcomes

  1. Change from baseline in serum bile acids levels

    Time frame: Baseline to week 72 (cohort 1).

  2. Change from baseline in patient reported and observer reported itching and scratching severity scores

    Assessed by the the Albireo ObsRO/ Patient Reported Outcomes (PRO) instruments. The Albireo ObsRO/PRO scratching and itch severity items use 0 to 4 response scales, where each response is distinguished by a unique facial expression, verbal anchor, number, and color code.

    Time frame: Baseline to week 72 (cohort 1).

  3. Percentage of participants achieving a clinically meaningful decrease in pruritus (pruritus responders)

    Assessed by the Albireo ObsRO/patient reported outcomes (PRO) instruments

    Time frame: Baseline to week 72 (cohort 1).

  4. Change from baseline in sleep parameters.

    Assessed with the Albireo ObsRO/PRO instruments (e.g: tiredness and number of awakenings).

    Time frame: Baseline to week 72 (cohort 1).

  5. Change from baseline in Pediatric Quality of Life Inventory (PedsQL) scores.

    The PedsQL instrument consists of 36 questions and uses a 5-point response scales, where higher scores indicates worst symptoms.

    Time frame: Baseline to week 72 (cohort 1).

  6. Change from baseline in in Global Symptom Relief: Patient Global Impression of Improvement (PGIC) score.

    The Patient Global Impression of Change (PGIC) is a patient-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

    Time frame: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

  7. Change from baseline in in Global Symptom Relief: Clinical Global Impression of Improvement (CGIC) score.

    The Clinical Global Impression of Change (CGIC) is a clinician-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

    Time frame: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

  8. Change from baseline in in Global Symptom Relief: Caregiver Global Impression of Change (CaGIC) score

    The caregiver Global Impression of Change is a caregiver-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

    Time frame: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

  9. Change from baseline in serum bile acid levels.

    Time frame: Baseline through week 72 (cohort 1).

  10. Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is an AE that resultes in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: Baseline to week 72 (cohort 1).

  11. Number of participants with change from baseline in physical examination

    Time frame: Baseline to week 72 (cohort 1).

  12. Number of participants with change from baseline in vital signs

    Time frame: Baseline to week 72 (cohort 1).

  13. Change from baseline in concomitant medications

    Time frame: Baseline to week 72 (cohort 1).

  14. Change from baseline in laboratory test results Pharmacokinetic (PK) Cmax [Time Frame: Day 1, Week 4, Week 8, and Week 12]

    Time frame: Baseline to week 72 (cohort 1).

  15. Change from baseline in plasma concentration of study drug

    Time frame: Day 1, Week 4, Week 8, and Week 12 (cohort 1).

  16. Pharmacodynamic Parameters: Change in serum bile acids levels

    Time frame: Baseline to Week 12 (cohort 2).

07

Study locations

35 sites
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2021 (actual). Primary completion is estimated for Feb 2027, 65 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Dec 2026 → Feb 2027 and completion Dec 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2021
First posted
Sep 5, 2021
StartActual
Sep 3, 2021
Primary completionEst.
Feb 15, 2027was Dec 2026
CompletionEst.
Feb 15, 2027was Dec 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Feb 15, 2027
Oct 23, 2026
Study completion
Dec 31, 2026→Feb 15, 2027
Oct 23, 2026
Show all 2 updates
  1. Oct 23, 2026
    Primary completion Dec 31, 2026→Feb 15, 2027
    Study completion Dec 31, 2026→Feb 15, 2027
    + 1 other change: verification date
  2. Oct 2, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05035030
Responsible party
Sponsor
First posted
Sep 5, 2021
Start date
Sep 3, 2021
Primary completion
Feb 15, 2027 (estimated)
Completion
Feb 15, 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Odevixibat

Start the discussion